Patents by Inventor Hartmut Lüss

Hartmut Lüss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Natriuretic Peptide for Treating Heart Failure
    Publication number: 20160324931
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: May 11, 2016
    Publication date: November 10, 2016
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of natriuretic peptide for treating heart failure
    Patent number: 9358271
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: June 7, 2016
    Assignee: Cardiorentis AG
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of Natriuretic Peptide for Treating Heart Failure
    Publication number: 20150224174
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: February 26, 2015
    Publication date: August 13, 2015
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of natriuretic peptide for treating heart failure
    Patent number: 9023794
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: May 5, 2015
    Assignee: Cardiorentis AG
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of Natriuretic Peptide for Treating Heart Failure
    Publication number: 20140287999
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: Cardiorentis Ltd.
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of natriuretic peptide for treating heart failure
    Patent number: 8710006
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 29, 2014
    Assignee: Cardiopep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of natriuretic peptide for treating heart failure
    Patent number: 7732406
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: June 8, 2010
    Assignee: CardioPep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Lüss, Wolf-Georg Forssmann, Markus Meyer, Klaus Döhler
  • Use of natriuretic peptide for treating heart failure
    Publication number: 20060264376
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 23, 2006
    Applicant: Cardiopep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler